Skip to main content

Table 1 Charateristics of included studies in the meta-analysis

From: Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

Study, year Subjects, N(p/c) Follow-up(weeks) Mean age (years) Type of Dialysis Baseline MBD Labs* Phosphate binders Dosing schedule Routine of administration Outcomes
        Paricalcitol Control   
Sprague 2003 [27] 263(130/133) 32 56.7 HD Ca 2.25 (2.25) mmol/LP 1.91 (1.87) mmol/LPTH 68.7 (71.6) pmol/L calcium carbonate calcium acetate Initial dose 0.04 μg/kg and increment of 0.04 μg/kg every 4 weeks. Maximum dose was 0.24 μg. Initial dose 0.01 μg/kg and increment of 0.01 μg/kg every 4 weeks. Maximum dose was 0.06 μg. IV 1,2,3,4
Gafor 2009 [26] 25(13/12) 12 48.2 HD Ca 2.29 (2.30) mmol/LP 1.58 (1.65) mmol/LPTH 136.8 (128.1) pmol/L calcium-containing Initial dose 0.04 μg/kg and increment of 0.04 μg/kg every 3 weeks. Initial dose 0.01 μg/kg and increment of 0.01 μg/kg every 3 weeks. IV 5,6,7
Lund 2010 [25] 18(9/9) 5 51.1 HD Ca 2.17 (2.22) mmol/LP 1.58 (1.71) mmol/LPTH 17.2 (14.6) pmol/L Sevelamer HCL Initial dose 0.06 μg/kg Initial dose 0.02 μg/kg IV 6,7
Hansen 2011 [24] 86(45/41) 16 63.7 HD Ca 1.15 (1.16) mmol/LaP 1.46 (1.48) mmol/LPTH 57.0 (60.0) pmol/L calcium-containing sevelamer Lanthanum Initial dose 9 μg/week, The median (range) final doses for the last 4 weeks: 18.1 μg/week (6.8–60.0 μg/week) Initial dose 3 μg/week, The median (range) final doses for the last 4 weeks: 5.3 μg/week (0.0–33.0 μg/week) IV 1,2,3,4,5,6,7,8
Ong 2013 [23] 66(36/30) 24 46.3 HD Ca 2.17 (2.12) mmol/LP 1.87 (1.72) mmol/LPTH 52.5 (59.2) pmol/L calcium carbonate Initial dose:(iPTH/12.7)μg, The mean maximal dose 29.6 μg; The mean weekly dose 20.9 μg Initial dose:(iPTH/38.1)μg, The mean maximal dose 9.9 μg; The mean weekly dose 7.1 μg PO 1,2,4,6,7
Jamaluddin 2014 [22] 26(12/14) 15 48.3 PD Ca 2.24 (2.25) mmol/LP 1.65 (2.02) mmol/LPTH 85.7 (98.9) pmol/L calcium carbonate Initial dose = iPTH/7 every other day up to a maximum initial dose of 32 μg. Initial dose 5 μg daily. PO 1,2
Akizawa 2015 [21] 255(127/128) 12 61.5 HD Ca 2.28 (2.28) mmol/LP 1.68 (1.69) mmol/LPTH 55.5 (55.9) pmol/L calcium-containing;non-Ca containing Initial dose 2 μg, adjusted ±1 μg based on protocol-specified criteria up to a maximum of 7 μg. Initial dose 5 μg (iPTH < 53 pmol/L) or 10 μg(iPTH > 53 pmol/L) adjusted ±2.5 μg based on protocol-specified criteria up to a maximum of 20 μg. IV 1,2,3
Veceric 2016 [28] 20(10/10) 12 56 HD Ca 2.23 (2.04) mmol/L
P 1.56 (1.54) mmol/L
PTH 63.8 (66.0) pmol/L
non-Ca containing Initial dose 2 μg; three times per week. Initial dose 0.5 μg; three times per week. PO NR
  1. P paricalcitol, C control; The control was calcitriol or alfacalcidol or maxacalcitol. NR not reported. MBD mineral and bone disease. PO oral, IV intravenous, HD hemodialysis, PD peritoneal dialysis, iPTH intact parathyroid hormone.
  2. Symbols: *Paricalcitol(control); a: Ionized calcium
  3. Outcomes: 1. Target reduction of iPTH from baseline; 2. Hypercalcemia; 3. Hyperphosphatemia; 4. Elevation in the calcium-phosphorus product; 5. End-of-treatment serum PTH; 6. End-of-treatment serum phosphorus; 7. End-of-treatment serum calcium; 8. All-cause mortality